نتایج جستجو برای: intrapleural fibrinolytic therapy

تعداد نتایج: 657043  

Journal: :The European respiratory journal 1996
D Bouros S Schiza N Tzanakis J Drositis N Siafakas

Intrapleural urokinase has not been evaluated systemically in terms of efficacy, safety, and cost of treatment in a large series of patients with complicated (parapneumonic) pleural effusions (CPE) and pleural empyemas (PE). Furthermore, the optimal dose and duration of treatment is not known. Twenty consecutive patients with multiloculated parapneumonic effusions (13 with CPE and 7 with PE), i...

Journal: :Chest 2021

TOPIC: Disorders of the Pleura TYPE: Original Investigations PURPOSE: Intrapleural fibrinolytic therapy (IPFT) with tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) has been shown to reduce need for surgical intervention complicated pleural effusion/empyema (CPE/empyema). For patients in whom tPA/DNase is likely fail, however, receipt this may simply delay inevitable. The goal s...

2014
Natalia Popowicz Francesco Piccolo Ranjan Shrestha Y C Gary Lee

Intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) therapy is being increasingly employed as an alternative to surgical intervention for the treatment of complicated parapneumonic effusions and empyema. Published cases are limited to one randomized control trial and few case reports. No data exist on employing sequential or repeated courses of intrapleural tPA/DNase t...

Journal: :Oncology reports 2013
Nan Du Xiaosong Li Fang Li Hui Zhao Zhongyi Fan Junxun Ma Yan Fu Huanrong Kang

Malignant pleural effusion (MPE) is a common complication of advanced non-small cell lung cancer (NSCLC). Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been shown to be efficient in suppressing the accumulation of pleural fluid. However, whether intrapleural delivery of bevacizumab can be used to treat MPE remains unknown. The aim of the pre...

Journal: :The New England journal of medicine 2011
Najib M Rahman Nicholas A Maskell Alex West Richard Teoh Anthony Arnold Carolyn Mackinlay Daniel Peckham Chris W H Davies Nabeel Ali William Kinnear Andrew Bentley Brennan C Kahan John M Wrightson Helen E Davies Clare E Hooper Y C Gary Lee Emma L Hedley Nicky Crosthwaite Louise Choo Emma J Helm Fergus V Gleeson Andrew J Nunn Robert J O Davies

BACKGROUND More than 30% of patients with pleural infection either die or require surgery. Drainage of infected fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve outcomes in an earlier, large, randomized trial. METHODS We conducted a blinded, 2-by-2 factorial trial in which 210 patients with pleural infection were randomly assigned to receive one of f...

Journal: :Journal of laboratory and precision medicine 2021

: Over 1.5 million patients are admitted to hospital with pneumonia in the United States each year. Up 50% of them can develop a parapneumonic effusion which is associated higher mortality. The incidence pleural infection continues rise, particularly elderly and those comorbidities. Parapneumonic effusions cover spectrum presentations from free-flowing ‘simple effusion’ septated ‘complicated (C...

Journal: :The New England journal of medicine 2005
Nicholas A Maskell Christopher W H Davies Andrew J Nunn Emma L Hedley Fergus V Gleeson Robert Miller Rhian Gabe Glyn L Rees Timothy E A Peto Mark A Woodhead Donald J Lane Janet H Darbyshire Robert J O Davies

BACKGROUND Intrapleural fibrinolytic agents are used in the drainage of infected pleural-fluid collections. This use is based on small trials that did not have the statistical power to evaluate accurately important clinical outcomes, including safety. We conducted a trial to clarify the therapeutic role of intrapleural streptokinase. METHODS In this double-blind trial, 454 patients with pleur...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید